News &amp; Updates

In the treatment of hypercholesterolemia, the investigational oral small-molecule PCSK9 inhibitor laroprovstat appears well tolerated and may help reduce low-density lipoprotein cholesterol (LDL-C) levels when used in combination with rosuvastatin, according to a phase I study.

Novel oral small-molecule PCSK9 inhibitor shows promise in hypercholesterolemia

Use of sotatercept in a patient with transplant-ineligible PAH on dual therapy

04 Jul 2026 by

This is a case of a 64-year-old woman with pulmonary arterial hypertension (PAH) poorly controlled on dual therapy, who was intolerant of selexipag and unsuitable for lung transplantation.

Use of sotatercept in a patient with transplant-ineligible PAH on dual therapy

Perfusion studies enhance benefits of mechanical thrombectomy for stroke beyond 6-hour window

04 Jul 2026 by

Cerebral perfusion studies (CPS) can enhance the benefits of mechanical thrombectomy (MT) beyond the standard 6-hour post-stroke window, although favourable functional outcomes remain achievable in a substantial proportion of patients selected based on clinical judgement alone without CPS. These findings, from a study by researchers at the University of Hong Kong (HKU), suggest that stroke patients should not be routinely denied treatment solely because of delayed presentation or lack of CPS availability.

Perfusion studies enhance benefits of mechanical thrombectomy for stroke beyond 6-hour window

CCB outperforms beta-blocker for managing hypertension in HFpEF

The oral dihydropyridine calcium channel blocker (CCB) amlodipine appears more beneficial than the beta-blocker metoprolol for managing hypertension in patients with heart failure with preserved ejection fraction (HFpEF), with greater effects on blood pressure (BP) control and exercise capacity, as shown in a randomized crossover trial.

CCB outperforms beta-blocker for managing hypertension in HFpEF

How does baricitinib compare in RA patients at risk of VTE?

Treatment with baricitinib misses the noninferiority mark against tumour necrosis factor inhibitors (TNFi) in active rheumatoid arthritis (RA) patients at risk for venous thromboembolism (VTE) with high baseline disease activity, reports a study.

How does baricitinib compare in RA patients at risk of VTE?

03 Jul 2026

Novel extended-release tablet superior to febuxostat at reducing SUA levels

An extended-release formulation, HR091506, performs better than febuxostat immediate release in lowering urate levels in patients with gout and hyperuricaemia, as shown in a phase III trial.

Novel extended-release tablet superior to febuxostat at reducing SUA levels

03 Jul 2026

$Substance use, poverty, race predictive of orbital, facial fractures$

Substance use, poverty, race predictive of orbital, facial fractures

Social determinants of health (SDOH) are significantly associated with maxillofacial trauma, suggests a US study. These SDOH factors include substance use, unhoused status, and poverty, among others

Substance use, poverty, race predictive of orbital, facial fractures

Mitapivat RISEs UP as a potential Tx alternative for sickle cell disease

In the phase III RISE UP trial, mitapivat—approved for pyruvate kinase (PK) deficiency and thalassemia—shows a strong antihaemolytic effect in individuals with sickle cell disease (SCD).

Mitapivat RISEs UP as a potential Tx alternative for sickle cell disease

Chronic airway diseases linked to increased pertussis infection risk

Patients with asthma and chronic obstructive pulmonary disease (COPD) appear to have an elevated risk of pertussis infection, according to the results of a systematic review and meta-analysis.

Chronic airway diseases linked to increased pertussis infection risk